Angle Share News (AGL)

Angle Information

Buy AGL Shares
Add AGL to Watchlist
Add AGL to Alert

Share Price Information for Angle (AGL)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 19.50

Bid: 19.00

Ask: 20.00

Change: 0.25 (1.30%)

Spread: 1.00 (5.263%)

Open: 19.25

High: 19.50

Low: 19.00

Prev. Close: 19.25

Last checked at -

IN BRIEF: Angle responds to additional information request from US FDA

Fri, 04th Jun 2021 18:02

Angle PLC - liquid biopsy company - Confirms that it has completed the work required to answer questions raised by US Food & Drug Administration in its additional information request and submitted the response. Angle says it continues to anticipate a regulatory decision from US regulator during the second half of 2021.

Current stock price: 128.00 pence

Year-to-date change: more than doubled from 47.75p on December 31

By Evelina Grecenko; evelinagrecenko@alliancenews.com

More News

28 Sep 2020 19:33

IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix

20 Aug 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

14 Aug 2020 12:41

Angle's Parsortix Able To Predict Patients' Response To Treatment

20 Jul 2020 20:03

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

20 Jul 2020 10:16

Angle's 'Parsortix' advantageous in breast cancer in new research

(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.

25 Jun 2020 12:22

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

18 Jun 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

10 Jun 2020 16:41

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

12 May 2020 18:54

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

12 May 2020 08:58

Angle upbeat on recent research using 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

28 Apr 2020 12:28

Latest Share Chat

Angle Share News (AGL)

Share Price Information for Angle (AGL)

IN BRIEF: Angle responds to additional information request from US FDA

IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix

UK Shareholder Meetings Calendar - Next 7 Days

Angle's Parsortix Able To Predict Patients' Response To Treatment

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

Angle's 'Parsortix' advantageous in breast cancer in new research

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

UK Earnings, Trading Statements Calendar - Next 7 Days

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Angle upbeat on recent research using 'Parsortix'

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

Angle works with skeleton R&D crew during lockdown

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Angle UK, US, Canada operations 'severely disrupted' by Covid-19

Angle Parsortix Test Used To Help Discover Brain Metastasis

Latest Share Chat

Angle Share News (AGL)

Share Price Information for Angle (AGL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Angle responds to additional information request from US FDA

Login to your account

Quickpicks are a member only feature

Login to your account